The cell viability results showed that the melanoma MeWo cell line was sensitized by all 3 combinations, except cilengitide + JNK-IN-8 paired with vemurafenib + trametinib (Supplementary Figure S8). This evidence concerns the gene MAPK8 and melanoma.